Incorporated in 1993, Artegraft Inc. offers surgeons a biological alternative to synthetic grafts. Artegraft’s natural collagen matrix has proven long-term patency advantages over ePTFE and other synthetic graft materials. Artegraft is also positioned as an alternative to a non-viable autogenous fistula. Artegraft was the first vascular graft approved by the FDA in 1970 and has been in continuous clinical use for over 50 years. Available in lengths from 15 to 50 cm and in 4, 5, 6, 7 and 8 mm inner diameters, Artegraft is approved for use, distal to the aorta, for segmental bypass, arterial replacement, patch graft, femoropopliteal bypass when the patient’s saphenous is absent or inadequate, but is predominantly used as a hemodialysis graft.
Artegraft is positioned in the market as a biological alternative to synthetic grafts, particularly ePTFE, a thermoplastic that was never designed to be punctured 312 times per year as a hemodialysis graft. Artegraft’s natural collagen matrix, as well as its surgical versatility and compliance, has proven long-term patency advantages over ePTFE and other synthetic graft materials. Artegraft is also positioned as an alternative to a non-viable autogenous fistula. Think of it as an Arterial Conduit in a Bottle™.
The Company’s management team has extensive experience in the medical device sector:
Richard Gibson, President and CEO. Rick has served in this capacity since 1996. Prior to Artegraft, he was the founder and chairman of a manufacturer of enteral delivery devices used for nutritional support, and held sales, marketing and business development positions with three other medical device manufacturers.
Cathleen VanDerVeer, Senior VP. Cathy has been with Artegraft for 25 years. With a mechanical engineering degree, she is responsible for operations, including manufacturing, administration, customer support and human resources.
Norris Horn, Senior VP & Chief Financial Officer. Norris has 45 years of experience in all financial aspects of the healthcare field including consumer, pharma and medical devices.
Warren Kirschbaum, VP of Sales. Warren has been working in medical devices for over 40 years, and is responsible for the company’s sales and marketing functions.
Sanjay Ahuja, Ph.D., VP of Scientific Affairs. Sanjay has over 25 years in life sciences with expertise in quality assurance and regulatory affairs. His four degrees include Life Sciences, Physics and Materials Science. He has 510(k), IDE, PMA, NDA experience and is responsible for quality, regulatory and compliance.
Steven Weinberg, Ph.D., VP of Clinical Affairs. With 45 years experience in the medical device sector, Steve has over 30 patents and publications and has contributed to several medical and biomaterial textbooks. With a background in Mechanical and Biomedical Engineering, his expertise is cardio/vascular devices.